FULC — Fulcrum Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $486.28m
- $272.17m
- $80.00m
- 57
- 28
- 98
- 65
Annual cashflow statement for Fulcrum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -70.8 | -80.8 | -110 | -97.3 | -9.72 |
| Depreciation | |||||
| Non-Cash Items | 7.28 | 11.7 | 13.5 | 8.81 | 10.2 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 7.5 | -11.9 | -3.09 | -4.61 | -4.25 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -53.7 | -78.5 | -97 | -91 | -2.22 |
| Capital Expenditures | -1.34 | -1.71 | -1.96 | -0.508 | -0.278 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -55.8 | -128 | 14.4 | -36.2 | 32.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -57.1 | -130 | 12.4 | -36.7 | 32.2 |
| Financing Cash Flow Items | -0.193 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 71.1 | 187 | 84.3 | 118 | 2.75 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -39.7 | -21.6 | -0.314 | -9.54 | 32.8 |